GERN

0.87074.63%
RJ

Robert Jay Spiegel

Independent Director

Dr. Robert Jay Spiegel, also known as Bob, FACP, M.D., is Independent Director of Ernexa Therapeutics Inc. from September 14, 2026. Dr. Spiegel is Special Advisor to CEO & Interim Chief Medical Officer of OYE Therapeutics, Inc. Dr. Spiegel was an Independent Vice Chairman of Cyclacel Pharmaceuticals, Inc. since November 2020 until January 2025 and was Independent Director September 6, 2018 until January 2025. He serves as Independent Director at RenovoRx, Inc. since April 25, 2023. He serves as Acting Chief Medical at Insilico Medicine, Inc. since September 2021. He serves as Member Scientific and Strategic Advisory Board at Adagene Inc. since August 2021. He serves as Independent Director of Sun Pharma Advanced Research Company Limited since June 1, 2020. He had been a Director of Athenex, Inc. since August 2020 until September 2023. He served as Member of Scientific Advisory Board at ABIONYX Pharma SA (formerly, Cerenis Therapeutics Holding SA) since May 2018. He was involved in the development of numerous cancer drugs and led the development of Remicade (infliximab), Temodar (temozolomide) and alpha-interferon (Intron A) through PH I-III studies, securing the first FDA approval for a biologic protein. Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics from March 2011 to April 2016. He has been Independent Director at Ayala Pharmaceuticals, Inc. (formerly known as Advaxis, Inc.) since October 19, 2023. Dr. Spiegel is an Independent Director of Geron Corporation since May 20, 2010. He served as Director of Edge Therapeutics, Inc (formerly Edge Therapeutics, Inc.) from August 2013 to March 26, 2019. He served as a Director of Avior Computing Corporation from October 2011 to November 2017; Talon Therapeutics, Inc. from July 2010 to July 2013; Capstone Therapeutics Corp. from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc. from January 2015 to January 2018; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. He is Chairman of Vidac Pharma. He was Chairman of NexImmune, Inc. and was its Director from 2017 to 2019. He had been a Director at Vidac Pharma Ltd. since June 29, 2016. He serves as the President of Spiegel Consulting LLC. Dr. Spiegel has served as an Associate Professor at the Weill Cornell Medical School since 2013. He is also a Senior Advisor of Warburg Pincus and an Advisor to the Israel Biotech Fund. Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the ScheringPlough Corporation. Following a fellowship at the National Institutes of Health in medical oncology, Dr. Spiegel was an Assistant Professor and Director of the Developmental Therapeutics Program at New York University Medical Center from September 1980 to November 1983 and then spent several years at Schering-Plough (now Merck & Co.) from November 1983 to December 2009, where he joined as the first Director for Oncology Clinical Research. He subsequently held a series of senior executive positions, including Senior Vice President for Worldwide Clinical Research and Chief Medical Officer. Dr. Spiegel received his B.A. from Yale University in 1971 and his M.D. from the University of Pennsylvania in 1975. Following his residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute.

Positions